(Q53787349)

English

Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/22959335

Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/22959335

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

Gerhard Ehninger

20

object named as

Gerhard Ehninger

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

Martin Bornhäuser

1

object named as

Martin Bornhäuser

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

Johannes Schetelig

22

object named as

Johannes Schetelig

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/22959335

Dietrich W Beelen

21

object named as

Dietrich W Beelen

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/22959335

Matthias Stelljes

23

object named as

Matthias Stelljes

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/22959335

Kerstin Schäfer-Eckart

8

object named as

Kerstin Schäfer-Eckart

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/22959335

13

object named as

Michael G Kiehl

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/22959335

Andreas Burchert

4

object named as

Andreas Burchert

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/22959335

Rainer Schwerdtfeger

15

object named as

Rainer Schwerdtfeger

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/22959335

Rudolf Trenschel

3

object named as

Rudolf Trenschel

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/22959335

5

object named as

Ute Hegenbart

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/22959335

Joachim Kienast

2

object named as

Joachim Kienast

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/22959335

Herrad Baurmann

7

object named as

Herrad Baurmann

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/22959335

Stefanie Buchholz

16

object named as

Stefanie Buchholz

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/22959335

Wolfgang Hiddemann

14

object named as

Wolfgang Hiddemann

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/22959335

17

object named as

Peter Dreger

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/22959335

author name string

Michael Stadler

6

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/22959335

Ernst Holler

9

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/22959335

Nicolaus Kröger

10

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/22959335

Christoph Schmid

11

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/22959335

Herrmann Einsele

12

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/22959335

Andreas Neubauer

18

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/22959335

Wolfgang E Berdel

19

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/22959335

publication date

7 September 2012

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/22959335

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/22959335

13

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/22959335

10

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/22959335

1035-1044

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/22959335

Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970349-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970349-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970349-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970349-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970349-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970349-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970349-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970349-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970349-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970349-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970349-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Non-parametric inference for cumulative incidence functions in competing risks studies.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970349-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970349-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970349-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970349-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970349-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970349-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A Prospective Multicenter Trial of Peripheral Blood Stem Cell Sibling Allografts for Acute Myeloid Leukemia in First Complete Remission Using Fludarabine-Cyclophosphamide Reduced Intensity Conditioning

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970349-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective s

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970349-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970349-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970349-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970349-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduced intensity versus myeloablative allogeneic stem cell transplantation for the treatment of acute myeloid leukemia, myelodysplastic syndrome and acute lymphoid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970349-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduced-intensity conditioning for acute myeloid leukemia: is this strategy correct

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970349-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimizing the conditioning regimen for allogeneic stem-cell transplantation in acute myeloid leukemia; dose intensity is still in need

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970349-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970349-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970349-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Graft-versus-leukemia reactions in allogeneic chimeras

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970349-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induc

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970349-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Serious acute or chronic graft-versus-host disease after hematopoietic cell transplantation: a comparison of myeloablative and nonmyeloablative conditioning regimens.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970349-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970349-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(12)70349-2

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/22959335

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/22959335

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53787349&oldid=1857469232"